Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
DEA proposes to expand List I chemical 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) to include its esters, affecting handlers and manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Chemical manufacturers, distributors, importers, and exporters of PMK glycidic acid and its esters; also downstream pharmaceutical manufacturers using these chemicals. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the excerpt; comment period and effective date not provided.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The DEA is proposing to amend the listing of List I chemical 3,4-MDP-2-P methyl glycidic acid to include its esters, which would subject esters to the same regulatory controls as the parent chemical.
Who it affects
Chemical manufacturers, distributors, importers, and exporters of PMK glycidic acid and its esters; also downstream pharmaceutical manufacturers using these chemicals.
What you must do
Review current handling and recordkeeping practices for PMK glycidic acid esters to ensure compliance with List I chemical regulations once the amendment is finalized.
Deadline
Not specified in the excerpt; comment period and effective date not provided.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- US-CONGRESS HR1266: Combating Illicit Xylazine Act
- Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs; Revised Draft Guidance for Industry; Availability
- Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
- PRESCRIPTION DRUGS—M.D. Tenn.: Court rejects AbbVie’s challenge to Tennessee contract pharmacy law - vitallaw.com
- WY HB0013: Ivermectin-no prescription required.